New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;ABC;CAH;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
May 13, 2015
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
May 12, 2015
16:20 EDTMCKMcKesson authorizes $500M repurchase program
Subscribe for More Information
16:18 EDTMCKMcKesson sees FY16 EPS $12.20-$12.70, consensus $12.57
Sees FY16 distribution solutions revenue growth in mid-single digits. Sees North America pharmaceutical distribution and services delivering high-single digit revenue growth. Sees international pharmaceutical and distribution services revenues flat year-over-year on constant currency basis. Sees medical-surgical distribution and services delivering mid-single digit revenue growth. Sees branded drug price trends in U.S. similar to FY15. Sees price trends on generic drugs outside an exclusivity period, in the U.S. market, slightly below FY15. Sees profit contribution from launch of new oral generic pharmaceuticals in the U.S. market decreasing. Sees technology solutions revenue declining mid-single digits driven by revenue decline in our hospital software business and pending sale of a business line. Guidance assumes adjusted tax rate 31.5%. Sees cash flow from operations $3B.
16:14 EDTMCKMcKesson reports Q4 adjusted adjusted EPS $2.94, consensus $2.75
Subscribe for More Information
15:00 EDTMCKNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include McKesson (MCK), consensus $2.75... Zillow (Z), consensus (12c)... GoDaddy (GDDY), consensus 35c... RSP Permian (RSPP), consensus 17c... Parsley Energy (PE), consensus 0c... Vivint Solar (VSLR), consensus (38c)... New Relic (NEWR), consensus (25c)... Hortonworks (HDP), consensus (86c)... SunOpta (STKL), consensus 7c... OPOWER (OPWR), consensus (16c)... JP Energy Partners (JPEP), consensus (4c)... TubeMogul (TUBE), consensus (18c)... Ducommun (DCO), consensus 30c.
07:56 EDTMCKMcKesson has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO John Hammergren on May 13 at 10:30 am.
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
May 11, 2015
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use